All posts by: Michael Zand

About Michael Zand

New Gene Editing Strategy Leads to Much Longer Protein Production – Muscular Dystrophy News

Continue reading

2018-04-04 NEWS

Muscular Dystrophy News

New Gene Editing Strategy Leads to Much Longer Protein Production
Muscular Dystrophy News
American researchers have developed a new way of delivering a gene editing therapy that significantly increases the time a repaired gene can generate the protein that’s missing in a disease. This means that a gene therapy does not have to be repeated

Continue reading

2018-04-04 NEWS

Benefit of GenSight’s gene therapy not so clear
BioPharma Dive
GenSight Biologics SA on April 3 announced topline results from the Phase 3 REVERSE trial that evaluated a single, intravitreal injection of its gene therapy candidate GS010 in 37 subjects with an inherited, degenerative eye disease who began losing

and more »

Continue reading

2018-04-04 NEWS

Xconomy

Lilly’s next diabetes play would have patients swallow engineered stem cells
BioPharma Dive
Eli Lilly & Co. and a freshly formed Massachusetts biotech are working to create a new kind of diabetes treatment: one that would have patients downing a capsule filled with insulin-producing cells. Sigilon Therapeutics Inc., which launched in mid-2017
Lilly Licenses Sigilon’s Cell Encapsulation Tech for Diabetes TherapyXconomy
Eli Lilly jumps into a $473M hunt with Sigilon for the Holy Grail in diabetes cell therapiesEndpoints News
Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the …Markets Insider
The Pharma Letter –FierceBiotech
all 79 news articles »
Continue reading

2018-04-04 NEWS

Stanford Medical Center Report

Scientists combine CRISPR, DNA barcoding to track cancer growth
Stanford Medical Center Report
The combination of CRISPR-Cas9 and DNA barcoding could allow scientists to replicate in the lab the kind of genetic diversity observed in cancer patients. “It gets around this fear of the complexity of cancer,” Winters said. “We’ve known for decades

Continue reading

2018-04-04 NEWS

Cincinnati Business Courier

Cintas Corp.’s Farmer family gives millions for stem cell research at local hospital
Cincinnati Business Courier
The scientists converted adult human cells drawn from skin and blood samples into blank stem cells, which can become any type of tissue. Today, doctors at the hospital can bioengineer the small intestine, colon, stomach and mini livers. Cincinnati